Correction to Safety Data in Aromatase Inhibitors and Growth Hormone Therapy Study

Overview

This correction clarifies the incidence of adverse symptoms reported in male adolescents treated with aromatase inhibitors combined with growth hormone. The number of children experiencing sleep problems and mental symptoms, as well as joint pain, was updated to reflect accurate counts.

Background

Aromatase inhibitors (AIs) combined with growth hormone therapy have been investigated as a treatment for idiopathic short stature in male adolescents. Monitoring adverse effects such as sleep disturbances, mental symptoms, and joint pain is critical to evaluating the safety profile of this combination therapy. Accurate reporting of these side effects informs clinical decision-making and patient counseling.

Data Highlights

Corrected symptom incidence during treatment:
- Sleep problems reported in 2 children
- Mental symptoms reported in 9 children
- Joint pain experienced by 11 children (8 in combined AIs group, 3 in combined GnRHa group)

Key Findings

• The number of children reporting sleep problems was corrected from 11 to 2.
• Mental symptoms such as memory loss and anxiety were reported in 9 children.
• Joint pain incidence was updated from 8 to 11 children overall.
• Within joint pain cases, 8 occurred in the combined aromatase inhibitors treatment group.
• Three cases of joint pain were reported in the combined GnRHa treatment group.

Clinical Implications

Clinicians should note the corrected lower incidence of sleep-related adverse effects but a higher incidence of joint pain than initially reported. These findings emphasize the importance of vigilant monitoring for musculoskeletal symptoms during therapy. Accurate adverse event data support informed risk-benefit discussions with patients and families.

Conclusion

The correction provides a more precise understanding of the safety profile of combined aromatase inhibitors and growth hormone therapy in male adolescents with idiopathic short stature. This ensures clinicians have reliable data to guide treatment and monitoring strategies.

References

1. Cui Y et al. 2025 -- Combining Aromatase Inhibitors with Growth Hormone Therapy for Male Adolescents with Idiopathic Short Stature (Correction)